Healius (HLS) AGM 2026 summary

Opening remarks and agenda

• Kate McKenzie opened the AGM after confirming a quorum; polls opened for all business and remained open until the meeting ended.

• Agenda covered Chair and CEO addresses, general questions and formal business; resolutions were decided by poll, with results to be released on the ASX.

Financial performance review

• FY26 revenue rose 2.1% to AUD 1.37bn; underlying EBITDA increased 8.1% to AUD 258.6m and underlying EBIT rose 76.6% to AUD 30.2m.

• FY26 average fee growth was 4.0% vs FY25; consumables were 15.3% of revenue vs 16.2% in the prior-year period.

• FY26 Genomics revenue rose 16.9%, Vetnostics revenue 3.4% and Clinical Trials revenue 92.9% YoY.

• Annualised corporate cost savings reached $24.4m; FY26 labour costs were flat and 49.7% of revenue.

• Q1 FY27 pathology revenue rose 1.6% despite episodes falling 4.9%; like-for-like volumes rose 1.1%. Average fee increased 6%, labour costs fell 1.4% and total costs fell 0.5%; FY27 EBIT guidance was reaffirmed.

Board and executive committee updates

• Steven Rubic joined the board in December 2025 and Professor Bruce Robinson in February 2026, adding healthcare, growth strategy and operational expertise.

• The Chair thanked directors who retired during the year; board succession and the mix of skills, including shareholder-focused capability, remain under review.